Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

29 Nov 2013

Abstract excerpt

Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown. Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. IKZF1 and IKZF3 are essential transcription factors in multiple myeloma. A single...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24292625
DOI: 10.1126/science.1244851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsPMID 24292625Read ↗

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomideSemantic proximity Read ↗

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read ↗

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read ↗

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaSemantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Semantic proximity Read ↗

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1Semantic proximity Read ↗

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsSemantic proximity Read ↗

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myelomaSemantic proximity Read ↗

Molecular and structural characterization of lenalidomide-mediated sequestration of eIF3iSemantic proximity Read ↗

ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells.Semantic proximity Read ↗

c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.